Corsera Health

Executive Summary

Corsera Health is a San Francisco-based biotechnology company founded in 2021 with a mission to predict and prevent atherosclerotic cardiovascular disease (ASCVD) before clinical onset. The company combines a proprietary AI-enabled risk prediction tool with RNA interference (RNAi) therapeutics to develop a once-annual preventive medicine that halts cumulative damage to the cardiovascular system. By shifting the paradigm from treatment to early prevention, Corsera aims to address the root cause of ASCVD, the leading cause of death globally. Its platform integrates machine learning algorithms that identify high-risk individuals years in advance, paired with a durable RNAi therapeutic designed to silence key drivers of atherosclerosis. This approach could dramatically reduce the burden of cardiovascular events if successful. As a private, early-stage company, Corsera will need to demonstrate preclinical proof-of-concept and secure funding to advance its lead candidate toward clinical trials. The convergence of AI in healthcare and RNAi technology positions Corsera at the forefront of precision preventive medicine, though the path to commercialization remains lengthy and uncertain.

Upcoming Catalysts (preview)

• H2 2026IND submission for lead RNAi candidate targeting PCSK9 or Lp(a)50% success
• Q3 2026Strategic partnership with a cardiovascular diagnostics or pharma company for AI risk prediction tool40% success
• Q4 2026Series A financing round to fund IND-enabling studies55% success